These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24410313)

  • 41. Successful management with clofarabine for refractory leukaemia in a young adult with chronic renal failure.
    Sudour H; Kimmoun A; Contet A; Clement L; Salmon A; Schmitt C; Chastagner P
    Am J Hematol; 2011 Mar; 86(3):321-3. PubMed ID: 21328440
    [No Abstract]   [Full Text] [Related]  

  • 42. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
    Faderl S; Garcia-Manero G; Jabbour E; Ravandi F; Borthakur G; Estrov Z; Gandhi V; Byrd AL; Kwari M; Cortes J; Kantarjian HM
    Cancer; 2012 Feb; 118(3):722-8. PubMed ID: 21751197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Faderl S; Ravandi F; Huang X; Garcia-Manero G; Ferrajoli A; Estrov Z; Borthakur G; Verstovsek S; Thomas DA; Kwari M; Kantarjian HM
    Blood; 2008 Sep; 112(5):1638-45. PubMed ID: 18565853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.
    Selleslag D; Suciu S; Meloni G; Muus P; Halkes CJ; Venditti A; Ramadan SM; Pruijt H; Meert L; Vignetti M; Marie JP; Wittnebel S; de Witte T; Amadori S; Willemze R; Baron F
    Haematologica; 2017 Feb; 102(2):e47-e51. PubMed ID: 27789677
    [No Abstract]   [Full Text] [Related]  

  • 45. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
    O'Connor D; Sibson K; Caswell M; Connor P; Cummins M; Mitchell C; Motwani J; Taj M; Vora A; Wynn R; Kearns PR
    Br J Haematol; 2011 Aug; 154(4):482-5. PubMed ID: 21689087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clofarabine in refractory Langerhans cell histiocytosis.
    Rodriguez-Galindo C; Jeng M; Khuu P; McCarville MB; Jeha S
    Pediatr Blood Cancer; 2008 Nov; 51(5):703-6. PubMed ID: 18623218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
    Choi J; Foss F
    Yale J Biol Med; 2006 Dec; 79(3-4):169-72. PubMed ID: 17940627
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
    Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
    Locke F; Agarwal R; Kunnavakkam R; van Besien K; Larson RA; Odenike O; Godley LA; Liu H; Le Beau MM; Gurbuxani S; Thirman MJ; Sipkins D; White C; Artz A; Stock W
    Bone Marrow Transplant; 2013 Nov; 48(11):1437-43. PubMed ID: 23771005
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine.
    Lim SH; Mcmahan J; Zhang J; Zhang Y
    Leuk Lymphoma; 2010 Dec; 51(12):2258-61. PubMed ID: 21067443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome.
    Buchholz S; Dammann E; Stadler M; Krauter J; Beutel G; Trummer A; Eder M; Ganser A
    Eur J Haematol; 2012 Jan; 88(1):52-60. PubMed ID: 21883483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy.
    Rudrapatna VK; Morley K; Boucher KM; Pierson AS; Shull CT; Kushner JP; Shami PJ
    Leuk Res; 2015 Aug; 39(8):835-9. PubMed ID: 26038120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
    Faderl S; Garcia-Manero G; Estrov Z; Ravandi F; Borthakur G; Cortes JE; O'Brien S; Gandhi V; Plunkett W; Byrd A; Kwari M; Kantarjian HM
    J Clin Oncol; 2010 Jun; 28(16):2755-60. PubMed ID: 20421540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
    J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
    Martin MG; Uy GL; Procknow E; Stockerl-Goldstein K; Cashen A; Westervelt P; Abboud CN; Augustin K; Luo J; DiPersio JF; Vij R
    Bone Marrow Transplant; 2009 Jul; 44(1):13-7. PubMed ID: 19139740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
    Kadia TM; Jabbour E; Kantarjian H
    Semin Oncol; 2011 Oct; 38(5):682-92. PubMed ID: 21943675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clofarabine and nelarabine: two new purine nucleoside analogs.
    Gandhi V; Plunkett W
    Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
    Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Scappaticci GB; Marini BL; Nachar VR; Uebel JR; Vulaj V; Crouch A; Bixby DL; Talpaz M; Perissinotti AJ
    Ann Hematol; 2018 Apr; 97(4):573-584. PubMed ID: 29288428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.